ClinicalTrials.gg
CompletedNCT02915783Updated Jan 17, 2023Results posted

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

A Phase 2 interventional study of lenvatinib and everolimus in Non Clear Cell Renal Cell Carcinoma (nccRCC), sponsored by Eisai Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-17.

Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies testing everolimus in Neoplasm Metastasis — 1 open to participants now, 2 under way, none of them phase 3. Everolimus · Neoplasm Metastasis.

Enrollment
18th of 35
41 · median 41
Started
2017
with 1 other
Phase 2
16 of 35
1 open now
Registered
31st of 35
by date
Lead sponsor
1 of 35
Eisai Inc.

Among the 35 studies testing everolimus in Neoplasm Metastasis, this one is the 18th largest by enrollment, is one of 2 that started in 2017, is one of 16 in phase 2, and was the 31st registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

1 of the 35 studies testing everolimus in Neoplasm Metastasis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About everolimus

Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing everolimus in Neoplasm Metastasis, or all of them as a file.
02

Study summary

This is a single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus in participants with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease. The primary objective of the study is to evaluate the objective response rate (ORR). This study consists of three phases: a Pretreatment Phase (Screening and Baseline Periods), a Treatment Phase (starting Cycle 1, Day 1), and a Posttreatment Phase (End of Treatment Visit and survival Follow-up).

03

Conditions studied

  • Non Clear Cell Renal Cell Carcinoma (nccRCC)

Browse trials for

Keywords

  • unresectable advanced
  • metastatic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females age ≥18 years at the time of form (ICF)
  • Participants with confirmed non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease. Participants must have one of the following subtypes of nccRCC: papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary carcinoma (RMC), or unclassified.
  • Radiologically meeting the following criteria:

    1. At least 1 lesion of ≥10 millimeters (mm) in the longest diameter for a nonlymph node or ≥15 mm in the short axis diameter for a lymph node that is serially measurable according to (RECIST) v1.1 using computerized tomography (CT) or magnetic resonance imaging (MRI);
    2. Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of subsequent progressive disease (substantial size increase of ≥20%) to be deemed a target lesion.
  • (ECOG) performance status of 0 to 1.
  • Blood pressure (BP) ≤140/90 millimeters of mercury (mmHg) at Screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1/Day 1.
  • Adequate renal function as evidenced by calculated ≥30 milliliters (mL)/minute according to the Cockcroft and Gault formula
  • Adequate bone marrow function:

    1. (ANC) ≥1.5 × 10\^9/liter (L);
    2. ≥10.0 grams per deciliter (g/dL) (can be corrected by growth factor or transfusion prior to first dose of study drug);
    3. count ≥100 × 10\^9/L
  • Adequate liver function:

    1. ≤1.5 × (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome;
    2. Alkaline phosphatase (ALP), (ALT), and aspartate aminotransferase (AST) ≤3 × ULN (≤5 × ULN if participant has liver ). If ALP is >3 × ULN (in the absence of liver metastases) or >5 × ULN (in the presence of liver metastases) AND participants are also known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.
  • Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  • Predominant clear cell renal cell carcinoma (RCC)
  • Prior anticancer chemotherapy or targeted therapy for advanced nccRCC
  • Prior exposure to lenvatinib or mammalian target of rapamycin (mTOR) inhibitor
  • Known intolerance to lenvatinib, everolimus (or other rapamycin derivatives), or any of the
  • Major surgery performed within 3 weeks prior to the first dose of study drugs or scheduled for major surgery during the study
  • Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition that might affect the absorption of lenvatinib or everolimus
  • Participants having >1+ proteinuria on urine dipstick testing will undergo 24 hour urine collection for quantitative assessment of proteinuria. Participants with urine protein ≥1 grams (g)/24 hours will be ineligible.
  • Fasting total cholesterol ˃300 milligrams (mg)/dL (or ˃7.75 millimoles [mmol]/L) or fasting triglycerides level ˃2.5 × . Note: these participants can be included after initiation or adjustment of lipid-lowering medication.
  • Uncontrolled diabetes as defined by fasting glucose >1.5 times the ULN. Note: In case this threshold is exceeded, these participants can only be included after initiation or adjustment of glucose-lowering medication.
  • Known history of, or any evidence of, interstitial lung disease or active noninfectious pneumonitis.
  • Significant cardiovascular impairment: history of (a) congestive heart failure greater than (NYHA) Class II; (b) unstable angina; (c) myocardial infarction; (d) stroke; or (e) cardiac arrhythmia associated with hemodynamic instability within 6 months of the first dose of study drugs
  • Prolongation of interval to >480 milliseconds (msec)
  • Known history of (HIV) positive
  • Known active (e.g., hepatitis B surface antigen [HBsAg] reactive) or (e.g., hepatitis C virus [HCV] RNA detected)
  • hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study drug
  • Participants with central nervous system (CNS) (e.g., brain or ) .
  • Other active (except definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix or bladder) within the past 24 months
  • Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [β-hCG] or human chorionic gonadotropin [hCG] test with a minimum sensitivity of 25 International Units [IU]/L or equivalent units of β-hCG or hCG). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug.
  • Females of who:

    1. Had unprotected sexual intercourse within 30 days before study entry and who do not agree to use a highly effective method of (e.g., total abstinence, an intrauterine device, a double-barrier method [such as a condom plus diaphragm with spermicide], a contraceptive implant, an oral contraceptive, or have a vasectomized partner with confirmed azoospermia) throughout the entire study period and for 28 days after study drug discontinuation
    2. Are currently abstinent, and do not agree to use a double-barrier method (as described above) or refrain from being sexually active during the study period or for 28 days after study drug discontinuation
    3. Are using hormonal contraceptives but are not on a stable dose of the same hormonal contraceptive product for at least 4 weeks before dosing and who do not agree to use the same contraceptive during the study or for 28 days after study drug discontinuation
    4. Are using oral hormonal contraceptives and who do not agree to add a barrier method • Note: All females will be considered to be of childbearing potential unless they are (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing).
  • Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (i.e., not of childbearing potential or practicing highly effective contraception throughout the study period or for 28 days after study drug discontinuation). No sperm donation is allowed during the study period and for 28 days after study drug discontinuation.
  • Evidence of clinically significant disease (e.g., cardiovascular, respiratory, gastrointestinal, renal, or infectious disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments
  • Any medical or other condition that in the opinion of the investigator(s) would preclude the participant's participation in a clinical study
  • Active and current use of illegal recreational drugs
  • Currently enrolled in another interventional clinical study or used any drug or device within the past 28 days preceding
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    lenvatinib 18 mg/day and everolimus 5 mg/day

    Participants will receive initial doses of lenvatinib 18 milligrams per day (mg/day) (one 10-mg capsule and two 4-mg capsules) and everolimus 5 mg/day (5-mg tablets). Capsules and tablets are to be taken orally in immediate succession once a day (QD), and dosing is recommended to occur at approximately the same time each morning (consistently either with or without food).

    Drug: lenvatinib · Drug: everolimus

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR was defined as the percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of the first dose of study drug to the date of the first documentation of disease progression or death, whichever occurred first (up to approximately 3 years 9 months)

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS was assessed by investigator per RECIST v1.1, defined as time from date of first dose of study drug to date of first documentation of progressive disease (PD) or death whichever occurred first. PD: greater than or equal to (\>=) 20% increase in sum of diameters of target lesions, reference-smallest sum recorded in study (sum at baseline if that was smallest). Sum of diameters must have absolute increase of \>=5 mm. Appearance of \>=1 new lesions also considered PD. PFS was analyzed using Kaplan Meier method. PFS was censored on date of last adequate radiologic assessment prior to new anticancer therapy, more than one missed visits, treatment discontinuation, and cutoff date when no PD or death occurred before any of these (on first dose of study treatment if no adequate post baseline tumor assessment was available), per publication by Food and Drug Administration (FDA) 'Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2007).

    Time frame: From the date of the first dose of study drug to the date of the first documentation of disease progression or death, whichever occurred first (up to approximately 3 years 9 months)

  2. Overall Survival (OS)

    OS was defined as the time from the date of the first dose of study drug until the date of death from any cause. OS was analyzed using Kaplan Meier method. In the absence of death before data cutoff, participants were censored either at the date last known to be alive or the date of data cutoff, whichever came earlier. Participants were followed for survival every 12 weeks after the end of treatment visit. If a clinic visit was not feasible, follow-up information was obtained via telephone or email.

    Time frame: From the date of the first dose of study drug until the date of death from any cause (up to approximately 4 years 8 months)

07

Results

Posted Jul 13, 2020

Participant flow

Participants took part in the study at 8 investigative sites in the United States from 20 February 2017 to 2 November 2021.

Participant flow — Overall Study
MilestoneLenvatinib 18 mg/Day + Everolimus 5 mg/Day
Started31
Completed7
Not completed24
Withdrew: Death21
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was assessed by the investigator based on Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. ORR was defined as the percentage of participants with confirmed best overall response (BOR) of complete response (CR) or partial response (PR). CR was defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (\<) 10 millimeters (mm). PR was defined as at least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of the first dose of study drug to the date of the first documentation of disease progression or death, whichever occurred first (up to approximately 3 years 9 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsLenvatinib 18 mg/Day + Everolimus 5 mg/Day
Objective Response Rate (ORR)25.8 (11.9 to 44.6)
SecondaryProgression-free Survival (PFS)

PFS was assessed by investigator per RECIST v1.1, defined as time from date of first dose of study drug to date of first documentation of progressive disease (PD) or death whichever occurred first. PD: greater than or equal to (\>=) 20% increase in sum of diameters of target lesions, reference-smallest sum recorded in study (sum at baseline if that was smallest). Sum of diameters must have absolute increase of \>=5 mm. Appearance of \>=1 new lesions also considered PD. PFS was analyzed using Kaplan Meier method. PFS was censored on date of last adequate radiologic assessment prior to new anticancer therapy, more than one missed visits, treatment discontinuation, and cutoff date when no PD or death occurred before any of these (on first dose of study treatment if no adequate post baseline tumor assessment was available), per publication by Food and Drug Administration (FDA) 'Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics (2007).

Time frame:
From the date of the first dose of study drug to the date of the first documentation of disease progression or death, whichever occurred first (up to approximately 3 years 9 months)
Reported as:
Median · months
Progression-free Survival (PFS)
monthsLenvatinib 18 mg/Day + Everolimus 5 mg/Day
Progression-free Survival (PFS)13.11 (5.49 to 24.21)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first dose of study drug until the date of death from any cause. OS was analyzed using Kaplan Meier method. In the absence of death before data cutoff, participants were censored either at the date last known to be alive or the date of data cutoff, whichever came earlier. Participants were followed for survival every 12 weeks after the end of treatment visit. If a clinic visit was not feasible, follow-up information was obtained via telephone or email.

Time frame:
From the date of the first dose of study drug until the date of death from any cause (up to approximately 4 years 8 months)
Reported as:
Median · months
Overall Survival (OS)
monthsLenvatinib 18 mg/Day + Everolimus 5 mg/Day
Overall Survival (OS)16.33 (9.23 to 33.22)

Adverse events

Collected over Serious and non-serious adverse events are reported from the first dose of study drug up to 28 days following last dose of study drug, or until resolution of adverse event, whichever occurred first (up to approximately 3 years 10 months) and as planned All-cause mortality is reported from the date of the first dose of study drug until the date of death from any cause (up to approximately 4 years 8 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib 18 mg/Day + Everolimus 5 mg/Day21/31 (67.7%)12/31 (38.7%)31/31 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventLenvatinib 18 mg/Day + Everolimus 5 mg/Day
NauseaGastrointestinal disorders3/31
VomitingGastrointestinal disorders3/31
PneumoniaInfections and infestations2/31
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/31
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/31
Cardiac arrestCardiac disorders1/31
Cardiac failureCardiac disorders1/31
DiarrhoeaGastrointestinal disorders1/31
FaecalomaGastrointestinal disorders1/31
Gastric ulcerGastrointestinal disorders1/31
Most frequent other events
Showing 10 of 212
Most frequent other events
EventLenvatinib 18 mg/Day + Everolimus 5 mg/Day
FatigueGeneral disorders22/31
DiarrhoeaGastrointestinal disorders18/31
NauseaGastrointestinal disorders18/31
Decreased appetiteMetabolism and nutrition disorders17/31
VomitingGastrointestinal disorders16/31
StomatitisGastrointestinal disorders12/31
Weight decreasedInvestigations12/31
HypertensionVascular disorders10/31
Abdominal painGastrointestinal disorders9/31
ProteinuriaRenal and urinary disorders9/31

Baseline characteristics

The full analysis set (FAS) included participants who received at least 1 dose of the study drugs.

Age, Continuous
Age, Continuous(years)Lenvatinib 18 mg/Day + Everolimus 5 mg/Day
Mean63.3 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib 18 mg/Day + Everolimus 5 mg/Day
Female11
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib 18 mg/Day + Everolimus 5 mg/Day
Hispanic or Latino1
Not Hispanic or Latino28
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib 18 mg/Day + Everolimus 5 mg/Day
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White27
More than one race0
Unknown or Not Reported3
08

Study locations

8 sites
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Massachusetts General Hospital Cancer Center
    Boston, Massachusetts 02214, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Texas Oncology
    Dallas, Texas 75254, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
09

References and documents

Publications

  • Hutson TE, Michaelson MD, Kuzel TM, Agarwal N, Molina AM, Hsieh JJ, Vaishampayan UN, Xie R, Bapat U, Ye W, Jain RK, Fishman MN. A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. Eur Urol. 2021 Aug;80(2):162-170. doi: 10.1016/j.eururo.2021.03.015. Epub 2021 Apr 16. PubMed 33867192 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2021, 56 months.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 56 months is above that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2016
First posted
Sep 27, 2016
StartActual
Feb 20, 2017
Primary completionActual
Nov 2, 2021
CompletionActual
Nov 2, 2021
Results first posted
Jul 13, 2020
Last update
Jan 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02915783
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Sep 27, 2016
Start date
Feb 20, 2017
Primary completion
Nov 2, 2021
Completion
Nov 2, 2021
Results posted
Jul 13, 2020
Last update
Jan 17, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Everolimus

Start the discussion